Cannabis and Ulcerative Colitis

Not medical advice

This article is not medical advice. Ulcerative colitis is a serious, sometimes life-threatening disease. Untreated or undertreated UC raises the risk of severe flares, hospitalization, colectomy, and colorectal cancer. Do not stop or substitute prescribed therapy based on anything you read here. Talk to a gastroenterologist before adding cannabis to your regimen, especially if you are on immunosuppressants, biologics, or anticoagulants.

Plain-language summary

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes ulcers in the colon and rectum, leading to bloody diarrhea, urgency, cramping, and fatigue. People with UC frequently turn to cannabis: survey data suggest roughly 15–20% of IBD patients are active users, and a much larger share has tried it ^[1][2].

The short version of the evidence:

• Cannabis (mostly THC-containing) helps some patients feel better — less pain, better appetite, better sleep, improved quality of life. Weak / limited
• Small randomized trials show improvement in symptom scores. Weak / limited
• The same trials generally do not show improvement in objective markers of inflammation (CRP, fecal calprotectin) or in what the colon looks like on endoscopy. Strong evidence
• No cannabis product is approved anywhere as a treatment for UC.

In other words: cannabis may treat how UC feels, not what UC is.

What probably works (relatively speaking)

Nothing about cannabis in UC is at the 'strong evidence' level. The best-supported uses are symptomatic:

• Improving quality of life and general well-being. A randomized, placebo-controlled trial of CBD-rich cannabis oil (cannabigerol/THC-containing) in mild-to-moderate UC by Irving et al. (2018) found improvement in patient-reported quality of life, though it failed its primary remission endpoint and had high dropout due to side effects ^[3]. Weak / limited
• Reducing disease-activity symptom scores. Naftali et al. (2021) randomized patients with moderately active UC to smoked cannabis cigarettes (THC ~80 mg/day) vs placebo for 8 weeks. The cannabis group had significant improvement in the clinical Lichtiger index and endoscopic Mayo subscore on symptom items, but no significant change in CRP or calprotectin ^[4]. Weak / limited
• Pain, appetite, sleep, and nausea — symptoms cannabis tends to help across many conditions, not specifically UC ^[5]. Weak / limited

These are real benefits for people living with a miserable disease, but they are downstream symptom effects, not disease modification.

What might work — uncertain or mixed

• Steroid sparing. Surveys and retrospective series suggest some patients reduce corticosteroid use after starting cannabis ^[2]. No controlled trial has confirmed this. Anecdote
• Topical/rectal cannabinoids. Preclinical animal models of colitis show benefit from CB1/CB2 agonists and from CBD, including reduced inflammation and tissue damage ^[6]. Human data is essentially absent. Weak / limited
• Pure CBD (no THC). A small RCT of oral CBD in UC by Irving et al. (2018) did not meet its primary endpoint; tolerability was poor at the doses used ^[3]. The signal, if any, was modest. Weak / limited
• Endocannabinoid system modulation. The gut expresses CB1, CB2, and related receptors, and endocannabinoid tone appears altered in IBD tissue ^[7]. This is a plausible mechanism but does not, by itself, prove clinical benefit. Disputed

What doesn't work or has weak evidence

• Inducing or maintaining true (objective) remission. Across the published RCTs, cannabis has not produced consistent improvement in endoscopic appearance, CRP, or fecal calprotectin ^[3][4][8]. Strong evidence for absence of disease-modifying effect at studied doses.
• Replacing mesalamine, immunomodulators, or biologics. No evidence supports this, and there is suggestive evidence it could be harmful: an observational study by Storr et al. found cannabis users with Crohn's disease (a related IBD) had higher rates of surgery, possibly because symptom masking delayed escalation of therapy ^[9]. Caution likely applies to UC. Weak / limited
• 'Indica strains are better for gut inflammation.' The indica/sativa labels do not reliably predict chemistry or clinical effect ^[10]. This is folklore, not pharmacology. No data
• CBD-only products marketed for 'gut healing.' No human trial supports mucosal healing from CBD in UC. No data

What we don't know

• Whether higher doses, longer treatment, or different cannabinoid ratios (e.g., CBG-rich, THCV-rich) could produce objective benefit. Trials so far have been short (8–10 weeks) and small (typically 20–60 patients).
• Whether rectal/topical delivery to inflamed mucosa would work where oral and inhaled have not.
• Whether cannabis interacts meaningfully with biologics like infliximab, vedolizumab, or ustekinumab. Plausible via CYP450 but not well characterized.
• Whether long-term cannabis use changes the natural history of UC — flare frequency, hospitalization, colectomy, cancer risk. No long-term controlled data exists.
• The role of the gut microbiome as a mediator. Interesting preclinical signals; no robust human data.

How it compares to standard treatments

Standard UC therapy has decades of high-quality evidence behind it:

• 5-ASAs (mesalamine, sulfasalazine): first-line for mild-moderate UC; induce and maintain remission with strong evidence and good safety ^[11].
• Corticosteroids: induce remission in flares; not for maintenance due to side effects.
• Immunomodulators (azathioprine, 6-MP): maintenance in steroid-dependent disease.
• Biologics and small molecules (infliximab, adalimumab, vedolizumab, ustekinumab, tofacitinib, upadacitinib, ozanimod): induce and maintain remission, with mucosal healing demonstrated in large RCTs ^[12].

Cannabis has no equivalent evidence base. The honest framing: standard therapies treat the disease; cannabis, at best, treats how the disease feels. They are not interchangeable. Cannabis may have a legitimate adjunctive role for residual symptoms (pain, appetite, sleep, anxiety, nausea) in patients already on appropriate UC therapy — ideally with the gastroenterologist's knowledge.

Risks and practical considerations

• Symptom masking. The biggest specific risk in IBD: cannabis blunts pain and may make a smoldering flare feel manageable while inflammation progresses. Monitor objective markers (calprotectin, CRP, endoscopy), not just how you feel.
• Cannabinoid hyperemesis syndrome (CHS). Chronic heavy users can develop cyclic vomiting and abdominal pain that mimics or worsens IBD symptoms ^[13]. Strong evidence
• Drug interactions. CBD is a meaningful inhibitor of CYP3A4 and CYP2C19 and can raise levels of tacrolimus, warfarin, and others ^[14]. Relevant if you are on immunosuppressants or anticoagulants.
• Psychiatric effects. THC can worsen anxiety; high doses and frequent use are associated with cannabis use disorder and, in vulnerable people, psychosis ^[15].
• Smoking. Inhaling combusted plant matter has its own respiratory harms; vaporization or oral routes are generally preferred for medical use.
• Pregnancy and breastfeeding. Avoid. Cannabis use in pregnancy is associated with adverse outcomes ^[16].
• Surgery. Tell your surgical team. Cannabis affects anesthesia requirements and post-op pain.

If you and your gastroenterologist decide to try cannabis as an adjunct, reasonable principles: start low, go slow, prefer products with known cannabinoid content, track symptoms and objective markers, and do not reduce proven UC therapy on your own.

Sources

How this page was made

Related

• Cannabis and Crohn's Disease — Cannabis reliably improves Crohn's symptoms in small trials but has not been shown to heal...